Quick Detail:
Product name
Finasteride Factory Supplying
Other name
PROSCAR;PROSTIDE
CAS register number
98319-26-7
Molecular formula
C23H36N2O2
Molecular weight
372.54
Molecular structure
Safe Proscar local Anesthetic Drugs Anodyne CAS 98319-26-7 Finasteride / Prostide
Melting point
253°C
Assay
99%
Product description:
Finasteride (brand names Proscar and Propecia by Merck, among other generic names) is a synthetic drug for the treatment of benign prostatic hyperplasia (BPH) and male pattern baldness (MPB). It is a type II 5α-reductase inhibitor. 5α-reductase is an enzyme that converts testosterone to dihydrotestosterone (DHT).
Physicians use finasteride for the treatment of benign prostatic hyperplasia (BPH), informally known as an enlarged prostate. The FDA-approved dose is 5 mg once a day. Six months or more of treatment with finasteride may be required to determine the therapeutic results of treatment. If the drug is discontinued, any therapeutic benefits reverse within about 6-8 months. Finasteride may improve the symptoms associated with BPH such as difficulty urinating, getting up during the night to urinate, hesitation at the start of urination, and decreased urinary flow.
As measured by hair counts, in a five-year study of men with mild to moderate hair loss, two out of three of the men who took 1 mg of finasteride daily regrew some hair. In contrast, all of the men in the study who were not taking finasteride lost hair. In the same study, based on photographs that were reviewed by an independent panel of dermatologists, 48% of those treated with finasteride experienced visible regrowth of hair, and a further 42% had no further loss. Average hair count in the treatment group remained above baseline, and showed an increasing difference from hair count in the placebo group, for all five years of the study. Finasteride is effective only for as long as it is taken; the hair gained or maintained is lost within 6-12 months of ceasing therapy. In clinical studies, finasteride, like minoxidil, was shown to work on both the crown area and the hairline, but is most successful in the crown area.
The FDA has added a warning to 5α-reductase inhibitors concerning an increased risk of high-grade prostate cancer.While the effect of finasteride on the risk of developing prostate cancer has not been established, evidence suggests it may temporarily reduce the growth and prevalence of benign prostate tumors, but could also mask the early detection of prostate cancer. The primary concern is patients who develop prostate cancer while taking finasteride for benign prostatic hyperplasia, which in turn could delay diagnosis and early treatment of the prostate cancer, thereby potentially increasing the risk of these patients developing high-grade prostate cancer.
The 2005 Prostate Cancer Prevention Trial (PCPT) showed at a dosage of 5 mg per day, as is commonly prescribed for BPH, participants taking finasteride were 25% less likely to have developed prostate cancer at the end of the trial compared to those taking a placebo. It appeared (incorrectly) that finasteride increased the specificity and selectivity of prostate cancer detection, thus creating an apparently increased rate of high Gleason grade tumor. A 2008 update of this study found that finasteride reduces the incidence of prostate cancer by 30%. In the original study, the smaller prostate caused by finasteride facilitated detection of cancer nests and aggressive-looking cells. Most of the men in the study who had both low and high-grade prostate cancer chose to be treated, and many had their prostates removed. A pathologist then carefully examined each of those 500 prostates and compared the kinds of cancers found at surgery to those initially diagnosed at biopsy. This study concluded that finasteride did not increase the risk of high-grade prostate cancer.
COA and HPLC:
COA:
Product name
Finasteride
Appearance
White crystalline powder
Assay(*)
98～101.0%
99.5%
Identification
By UV, To match with working standard
Complies
Related Substances
Not more than the reference solution (0.05%)
Complies
Heavy metals
≤10ppm
8ppm
Loss on drying
<0.5%
0.1%
Resiue on ignition
≤0.1%
0.03%
Melting
253°C
Complies
For detail, please contact:
Dawn (miss)
Email: cherry@ycphar.com
Skype: dong.wen6
Our website: http://steroid.en.made-in-china.com
Permanent link: http://www.vvchem.com/sell/cas:98319-26-7,3288333.html
China
